These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19040717)

  • 41. Cost-Effectiveness Of The Sugar-Sweetened Beverage Excise Tax In Mexico.
    Basto-Abreu A; Barrientos-Gutiérrez T; Vidaña-Pérez D; Colchero MA; Hernández-F M; Hernández-Ávila M; Ward ZJ; Long MW; Gortmaker SL
    Health Aff (Millwood); 2019 Nov; 38(11):1824-1831. PubMed ID: 31682510
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness of interventions for reducing road traffic injuries related to driving under the influence of alcohol.
    Ditsuwan V; Lennert Veerman J; Bertram M; Vos T
    Value Health; 2013; 16(1):23-30. PubMed ID: 23337212
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness of the COPD Patient Management European Trial home-based disease management program.
    Bourbeau J; Granados D; Roze S; Durand-Zaleski I; Casan P; Köhler D; Tognella S; Viejo JL; Dal Negro RW; Kessler R
    Int J Chron Obstruct Pulmon Dis; 2019; 14():645-657. PubMed ID: 30936689
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Estimated health benefits, costs, and cost-effectiveness of eliminating industrial trans-fatty acids in Australia: A modelling study.
    Marklund M; Zheng M; Veerman JL; Wu JHY
    PLoS Med; 2020 Nov; 17(11):e1003407. PubMed ID: 33137090
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
    Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
    J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effectiveness and cost-effectiveness of policies and programmes to reduce the harm caused by alcohol.
    Anderson P; Chisholm D; Fuhr DC
    Lancet; 2009 Jun; 373(9682):2234-46. PubMed ID: 19560605
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Web-Based Computer-Tailored Alcohol Prevention Program for Adolescents: Cost-Effectiveness and Intersectoral Costs and Benefits.
    Drost RM; Paulus AT; Jander AF; Mercken L; de Vries H; Ruwaard D; Evers SM
    J Med Internet Res; 2016 Apr; 18(4):e93. PubMed ID: 27103154
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alcohol policy--evaluating the options.
    Maynard A; Godfrey C
    Br Med Bull; 1994 Jan; 50(1):221-30. PubMed ID: 8149197
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines.
    Ramos IC; Versteegh MM; de Boer RA; Koenders JMA; Linssen GCM; Meeder JG; Rutten-van Mölken MPMH
    Value Health; 2017 Dec; 20(10):1260-1269. PubMed ID: 29241885
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
    Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
    Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes.
    van Giessen A; Boonman-de Winter LJ; Rutten FH; Cramer MJ; Landman MJ; Liem AH; Hoes AW; Koffijberg H
    Cardiovasc Diabetol; 2016 Mar; 15():48. PubMed ID: 27001409
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Real or perceived impediments to minimum pricing of alcohol in Australia: public opinion, the industry and the law.
    Chalmers J; Carragher N; Davoren S; O'Brien P
    Int J Drug Policy; 2013 Nov; 24(6):517-23. PubMed ID: 23773685
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Alcohol tax changes and the use of alcohol in Europe.
    Österberg EL
    Drug Alcohol Rev; 2011 Mar; 30(2):124-9. PubMed ID: 21375612
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk-based, 6-monthly and 24-monthly dental check-ups for adults: the INTERVAL three-arm RCT.
    Clarkson JE; Pitts NB; Goulao B; Boyers D; Ramsay CR; Floate R; Braid HJ; Fee PA; Ord FS; Worthington HV; van der Pol M; Young L; Freeman R; Gouick J; Humphris GM; Mitchell FE; McDonald AM; Norrie JD; Sim K; Douglas G; Ricketts D
    Health Technol Assess; 2020 Nov; 24(60):1-138. PubMed ID: 33215986
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Weakness of Stern Alcohol Control Policies.
    Poikolainen K
    Alcohol Alcohol; 2016 Jan; 51(1):93-7. PubMed ID: 26152817
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness of transcatheter aortic valve replacement compared with standard care among inoperable patients with severe aortic stenosis: results from the placement of aortic transcatheter valves (PARTNER) trial (Cohort B).
    Reynolds MR; Magnuson EA; Wang K; Lei Y; Vilain K; Walczak J; Kodali SK; Lasala JM; O'Neill WW; Davidson CJ; Smith CR; Leon MB; Cohen DJ;
    Circulation; 2012 Mar; 125(9):1102-9. PubMed ID: 22308299
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of mandatory bicycle helmet use to prevent traumatic brain injuries and death.
    Reuvers R; Over EAB; Suijkerbuijk AWM; Polder JJ; de Wit GA; van Gils PF
    BMC Public Health; 2020 Mar; 20(1):413. PubMed ID: 32228524
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Assessing long-run economic benefits attributed to an IVF-conceived singleton based on projected lifetime net tax contributions in the UK.
    Connolly M; Gallo F; Hoorens S; Ledger W
    Hum Reprod; 2009 Mar; 24(3):626-32. PubMed ID: 19056775
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.